Hikma Pharmaceuticals’ (LON:HIK) Underweight Rating Reiterated at Barclays

Barclays reiterated their underweight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report report published on Thursday, July 19th.

Several other equities research analysts also recently weighed in on HIK. Citigroup boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,250 ($16.18) to GBX 1,475 ($19.09) and gave the stock a buy rating in a research report on Tuesday, May 1st. Numis Securities lowered shares of Hikma Pharmaceuticals to an add rating and upped their price target for the stock from GBX 1,300 ($16.83) to GBX 1,560 ($20.19) in a research note on Friday, May 18th. Peel Hunt reissued a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, April 4th. Finally, Jefferies Financial Group restated a hold rating and set a GBX 997 ($12.91) price target on shares of Hikma Pharmaceuticals in a report on Friday, May 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company’s stock. Hikma Pharmaceuticals currently has an average rating of Hold and an average target price of GBX 1,151.70 ($14.91).

Shares of Hikma Pharmaceuticals traded up GBX 2.50 ($0.03), hitting GBX 1,673 ($21.66), during midday trading on Thursday, MarketBeat.com reports. 658,905 shares of the company’s stock traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($10.54) and a twelve month high of GBX 2,346 ($30.37).

In other news, insider Sigurdur Olafsson acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The stock was acquired at an average price of GBX 1,309 ($16.94) per share, with a total value of £261,800 ($338,899.68). Also, insider John J. Castellani acquired 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 22nd. The shares were purchased at an average cost of GBX 1,377 ($17.83) per share, with a total value of £13,770 ($17,825.24).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

See Also: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply